Literature DB >> 31288631

Generation of Quiescent Cardiac Fibroblasts From Human Induced Pluripotent Stem Cells for In Vitro Modeling of Cardiac Fibrosis.

Hao Zhang1,2,3, Lei Tian1,2,3, Mengcheng Shen1,2,3, Chengyi Tu1,2,3, Haodi Wu1,2,3, Mingxia Gu2,4,5, David T Paik1,2,3, Joseph C Wu1,2,3.   

Abstract

RATIONALE: Activated fibroblasts are the major cell type that secretes excessive extracellular matrix in response to injury, contributing to pathological fibrosis and leading to organ failure. Effective anti-fibrotic therapeutic solutions, however, are not available due to the poorly defined characteristics and unavailability of tissue-specific fibroblasts. Recent advances in single-cell RNA-sequencing fill such gaps of knowledge by enabling delineation of the developmental trajectories and identification of regulatory pathways of tissue-specific fibroblasts among different organs.
OBJECTIVE: This study aims to define the transcriptome profiles of tissue-specific fibroblasts using recently reported mouse single-cell RNA-sequencing atlas and to develop a robust chemically defined protocol to derive cardiac fibroblasts (CFs) from human induced pluripotent stem cells for in vitro modeling of cardiac fibrosis and drug screening. METHODS AND
RESULTS: By analyzing the single-cell transcriptome profiles of fibroblasts from 10 selected mouse tissues, we identified distinct tissue-specific signature genes, including transcription factors that define the identities of fibroblasts in the heart, lungs, trachea, and bladder. We also determined that CFs in large are of the epicardial lineage. We thus developed a robust chemically defined protocol that generates CFs from human induced pluripotent stem cells. Functional studies confirmed that iPSC-derived CFs preserved a quiescent phenotype and highly resembled primary CFs at the transcriptional, cellular, and functional levels. We demonstrated that this cell-based platform is sensitive to both pro- and anti-fibrosis drugs. Finally, we showed that crosstalk between human induced pluripotent stem cell-derived cardiomyocytes and CFs via the atrial/brain natriuretic peptide-natriuretic peptide receptor-1 pathway is implicated in suppressing fibrogenesis.
CONCLUSIONS: This study uncovers unique gene signatures that define tissue-specific identities of fibroblasts. The bona fide quiescent CFs derived from human induced pluripotent stem cells can serve as a faithful in vitro platform to better understand the underlying mechanisms of cardiac fibrosis and to screen anti-fibrotic drugs.

Entities:  

Keywords:  fibroblasts; fibrosis; induced pluripotent stem cells; transcriptome

Mesh:

Substances:

Year:  2019        PMID: 31288631      PMCID: PMC6768436          DOI: 10.1161/CIRCRESAHA.119.315491

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  37 in total

Review 1.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

Review 2.  Forcing cells to change lineages.

Authors:  Thomas Graf; Tariq Enver
Journal:  Nature       Date:  2009-12-03       Impact factor: 49.962

3.  TIMP-2 is required for efficient activation of proMMP-2 in vivo.

Authors:  Z Wang; R Juttermann; P D Soloway
Journal:  J Biol Chem       Date:  2000-08-25       Impact factor: 5.157

4.  Fibrosis, not cell size, delineates beta-myosin heavy chain reexpression during cardiac hypertrophy and normal aging in vivo.

Authors:  Kumar Pandya; Hyung-Suk Kim; Oliver Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-26       Impact factor: 11.205

5.  Tbx20 is essential for cardiac chamber differentiation and repression of Tbx2.

Authors:  Manvendra K Singh; Vincent M Christoffels; José M Dias; Mark-Oliver Trowe; Marianne Petry; Karin Schuster-Gossler; Antje Bürger; Johan Ericson; Andreas Kispert
Journal:  Development       Date:  2005-05-18       Impact factor: 6.868

6.  Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase.

Authors:  James S Swaney; David M Roth; Erik R Olson; Jennifer E Naugle; J Gary Meszaros; Paul A Insel
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-29       Impact factor: 11.205

7.  Kruppel-like factor 4 abrogates myocardin-induced activation of smooth muscle gene expression.

Authors:  Yan Liu; Sanjay Sinha; Oliver G McDonald; Yueting Shang; Mark H Hoofnagle; Gary K Owens
Journal:  J Biol Chem       Date:  2004-12-28       Impact factor: 5.157

8.  GATA4 is essential for formation of the proepicardium and regulates cardiogenesis.

Authors:  Alistair J Watt; Michele A Battle; Jixuan Li; Stephen A Duncan
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-13       Impact factor: 11.205

9.  Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression.

Authors:  Zhigao Wang; Da-Zhi Wang; Dirk Hockemeyer; John McAnally; Alfred Nordheim; Eric N Olson
Journal:  Nature       Date:  2004-03-11       Impact factor: 49.962

10.  Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis.

Authors:  Karlin Raja Karlmark; Ralf Weiskirchen; Henning W Zimmermann; Nikolaus Gassler; Florent Ginhoux; Christian Weber; Miriam Merad; Tom Luedde; Christian Trautwein; Frank Tacke
Journal:  Hepatology       Date:  2009-07       Impact factor: 17.425

View more
  34 in total

1.  SLIT3 deficiency attenuates pressure overload-induced cardiac fibrosis and remodeling.

Authors:  Lianghui Gong; Shuyun Wang; Li Shen; Catherine Liu; Mena Shenouda; Baolei Li; Xiaoxiao Liu; John A Shaw; Alan L Wineman; Yifeng Yang; Dingding Xiong; Anne Eichmann; Sylvia M Evans; Stephen J Weiss; Ming-Sing Si
Journal:  JCI Insight       Date:  2020-06-18

Review 2.  Human pluripotent stem cell-derived cardiac stromal cells and their applications in regenerative medicine.

Authors:  Martha E Floy; Taylor D Mateyka; Koji L Foreman; Sean P Palecek
Journal:  Stem Cell Res       Date:  2020-04-27       Impact factor: 2.020

Review 3.  Deconvoluting the Cells of the Human Heart with iPSC Technology: Cell Types, Protocols, and Uses.

Authors:  Brian Yu; Shane Rui Zhao; Christopher D Yan; Mao Zhang; Joseph C Wu
Journal:  Curr Cardiol Rep       Date:  2022-03-04       Impact factor: 2.931

4.  A Critical Role for Estrogen-Related Receptor Signaling in Cardiac Maturation.

Authors:  Tomoya Sakamoto; Timothy R Matsuura; Shibiao Wan; David M Ryba; J Unil Kim; Kyoung Jae Won; Ling Lai; Christopher Petucci; Nataliya Petrenko; Kiran Musunuru; Rick B Vega; Daniel P Kelly
Journal:  Circ Res       Date:  2020-03-26       Impact factor: 17.367

Review 5.  Human iPS Cell-derived Tissue Engineered Vascular Graft: Recent Advances and Future Directions.

Authors:  Xiangyu Shi; Lile He; Shang-Min Zhang; Jiesi Luo
Journal:  Stem Cell Rev Rep       Date:  2020-11-23       Impact factor: 5.739

Review 6.  Reconstructing the heart using iPSCs: Engineering strategies and applications.

Authors:  Sangkyun Cho; Chelsea Lee; Mark A Skylar-Scott; Sarah C Heilshorn; Joseph C Wu
Journal:  J Mol Cell Cardiol       Date:  2021-04-22       Impact factor: 5.000

Review 7.  Controlling cardiac fibrosis through fibroblast state space modulation.

Authors:  Isabella M Reichardt; Kalen Z Robeson; Michael Regnier; Jennifer Davis
Journal:  Cell Signal       Date:  2020-12-16       Impact factor: 4.315

Review 8.  Complex Relationship Between Cardiac Fibroblasts and Cardiomyocytes in Health and Disease.

Authors:  Caitlin Hall; Katja Gehmlich; Chris Denning; Davor Pavlovic
Journal:  J Am Heart Assoc       Date:  2021-02-15       Impact factor: 5.501

9.  A protocol for transdifferentiation of human cardiac fibroblasts into endothelial cells via activation of innate immunity.

Authors:  Chun Liu; Pedro Medina; Dilip Thomas; Ian Y Chen; Karim Sallam; Danish Sayed; Nazish Sayed
Journal:  STAR Protoc       Date:  2021-06-05

Review 10.  Inflammasomes and Fibrosis.

Authors:  Wen-Juan Zhang; Shu-Juan Chen; Shun-Chang Zhou; Su-Zhen Wu; Hui Wang
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.